Collectively, these data provide converging evidence from transcriptomic and proteomic levels that SSTR2 is frequently, though variably, expressed in HCC, supporting its further investigation as a clinically relevant biomarker and potential therapeutic target. The gene discussed is SSTR2; the disease is hepatocellular carcinoma.